Roy Straver

Senior Scientist

Universitair Medisch Centrum Utrecht
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2025

Nanopore sequencing allows identification of base modifications, such as methylation, directly from raw current data. Prevailing approaches, including deep learning (DL) methods, require training data covering all possible sequence contexts. These data can be prohibitively expensive or impossible to obtain for some modifications. Hence, research into DNA modifications focuses on the most prevalent modification in human DNA: 5mC in a CpG context. Improved generalization is required to reach the technology’s full potential: calling any modification from raw current values. We developed ReQuant, an algorithm to impute full, k-mer based, modification models from limited k-mer context training data. ReQuant is highly accurate for calling modifications (CpG/GpC methylation and CpG glucosylation) in Lambda Phage R9 data when fitting on ≤25% of all possible 6-mers with a modification and extends to human R10 data. The success of our approach shows that DNA modifications have a consistent and therefore predictable effect on Nanopore current levels, suggesting that interpretable rule-based imputation in unseen contexts is possible. Our approach circumvents the need for modification-specific DL tools and enables modification calling when not all sequence contexts can be obtained, opening a vast field of biological base modification research.

Year:

2025

The complex 2 Mb survival motor neuron (SMN) locus on chromosome 5q13, including the spinal muscular atrophy (SMA)-causing gene SMN1 and modifier SMN2 , remains incompletely resolved due to numerous segmental duplications. Variation in SMN2 copy number, presumably influenced by SMN1 to SMN2 gene conversion, affects disease severity, though SMN2 copy number alone has insufficient prognostic value due to limited genotype-phenotype correlations. With advancements in newborn screening and SMN -targeted therapies, identifying genetic markers to predict disease progression and treatment response is crucial. Progress has thus far been limited by methodological constraints. To address this, we used targeted nanopore long-read sequencing to analyze copy-specific variation in SMN and neighboring genes. In 25 healthy controls, we identified single nucleotide variants (SNVs) specific to SMN1 and SMN2 haplotypes that could serve as gene conversion markers. In 31 SMA patients, 45% of haplotypes showed varying SMN1 to SMN2 gene conversion breakpoints, serving as direct evidence of gene conversion as a common genetic characteristic in SMA and prompting further investigation into gene conversion markers as disease modifiers. Our findings illustrate that both methodological advances and the analysis of patient samples are required to advance our understanding of complex genetic loci and address critical clinical challenges.

Year:

2024

Year:

2023

Collaborators (5)

Boudewijn Burgering

University Medical Center Groningen

NETHERLANDS
View details

Gijs van Haaften

Associate Professor

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Ewout J. N. Groen

Associate professor

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Jan Veldink

Professor of Neurology and Neurogenetics

University Medical Center Utrecht, Utrecht University

NETHERLANDS
View details

Hanneke W. M. van Deutekom

Head of Bioinformatics

University Medical Center Groningen

NETHERLANDS
View details